Erratum: MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma (Nature Communications (2011) 2 (338) DOI: 10.1038/ncomms1345);MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma

Nature Communications

Volumn 2, Issue 1, 2011, Pages

  Kojima, Kentaro ^a   Takata, Akemi ^a   Vadnais, Charles ^b   Otsuka, Motoyuki ^a   Yoshikawa, Takeshi ^a   Akanuma, Masao ^c   Kondo, Yuji ^a   Kang, Young Jun ^d   Kishikawa, Takahiro ^a   Kato, Naoya ^e   Xie, Zhifang ^f   Zhang, Weiping J ^f   Yoshida, Haruhiko ^a   Omata, Masao ^a   Nepveu, Alain ^b   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUTE FOR ADULT DISEASES   (Japan)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CELL PROTEIN; MICRORNA; CUTL1 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; MIRN122 MICRORNA, MOUSE; MIRN214 MICRORNA, MOUSE; NUCLEAR PROTEIN; PRIMER DNA; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR; ZBTB20 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; XENOGRAFT; ANIMAL; CHROMATIN IMMUNOPRECIPITATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; LIVER TUMOR; METABOLISM; NORTHERN BLOTTING; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

MUS MUSCULUS;

ALPHA-FETOPROTEINS; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC; MICRORNAS; NUCLEAR PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 79958277000     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2081     Document Type: Erratum

References (58)

1. Parkin, D., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. El-Serag, H. Epidemiology of hepatocellular carcinoma in USA. Hepatol. Res. 37, S88-94 (2007).
3. Llovet, J. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
4. Greten, T. et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br. J. Cancer 92, 1862-1868 (2005). (Pubitemid 40826134)
5. Greten, T., Korangy, F., Manns, M. & Malek, N. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer 100, 19-23 (2009).
6. Di Bisceglie, A. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127, S104-S107 (2004). (Pubitemid 39423376)
7. Ogden, S. et al. p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression. J. Biol. Chem. 276, 42057-42062 (2001).
8. Peng, S. et al. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: signifcance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int. J. Cancer. 112, 44-50 (2004). (Pubitemid 39249490)
9. Xie, Z. et al. Zinc fnger protein ZBTB20 is a key repressor of alpha-fetoprotein gene transcription in liver. Proc. Natl Acad. Sci. USA 105, 10859-10864 (2008).
10. Oishi, K. et al. Clinicopathologic features of poorly diferentiated hepatocellular carcinoma. J. Surg. Oncol. 95, 311-316 (2007). (Pubitemid 46355507)
11. Yamamoto, K. et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J. Gastroenterol. 45, 1272-1282 (2010).
12. Matsumoto, Y. et al. Clinical classifcation of hepatoma in Japan according to serial changes in serum alpha-fetoprotein levels. Cancer 49, 354-360 (1982). (Pubitemid 12211853)
13. Lee, R., Feinbaum, R. & Ambros, V. Te C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993). (Pubitemid 24014542)
14. Carrington, J. & Ambros, V. Role of microRNAs in plant and animal development. Science 301, 336-338 (2003). (Pubitemid 36877060)
15. Bartel, D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
16. Ambros, V. Te functions of animal microRNAs. Nature 431, 350-355 (2004).
17. Lu, J. et al. MicroRNA expression profles classify human cancers. Nature 435, 834-838 (2005). (Pubitemid 40839735)
18. Landgraf, P. et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129, 1401-1414 (2007). (Pubitemid 46970709)
19. Krützfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689 (2005).
20. Esau, C. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87-98 (2006).
21. Gatfeld, D. et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 23, 1313-1326 (2009).
22. Yan, D. et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J. Biol. Chem. 284, 29596-29604 (2009).
23. Kutay, H. et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell. Biochem. 99, 671-678 (2006). (Pubitemid 44521987)
24. Coulouarn, C., Factor, V., Andersen, J., Durkin, M. & Torgeirsson, S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28, 3526-3536 (2009).
25. Tsai, W. et al. MicroRNA-122 a tumor suppressor microRNA that regulates intra-hepatic metastasis of hepatocellular carcinoma. Hepatology 49, 1571-1582 (2009).
26. Varnholt, H. et al. MicroRNA gene expression profle of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47, 1223-1232 (2008). (Pubitemid 351547908)
27. Wong, Q. et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135, 257-269 (2008). (Pubitemid 351910680)
28. Sahai, E. & Marshall, C. RHO-GTPases and cancer. Nat. Rev. Cancer 2, 133-142 (2002).
29. Sansregret, L. & Nepveu, A. Te multiple roles of CUX1: insights from mouse models and cell-based assays. Gene 412, 84-94 (2008).
30. Sansregret, L. et al. Cut homeobox 1 causes chromosomal instability by promoting bipolar division afer cytokinesis failure. Proc. Natl Acad. Sci. USA 108, 1949-1954 (2011).
31. Kedinger, V. & Nepveu, A. Te roles of CUX1 homeodomain proteins in the establishment of a transcriptional program required for cell migration and invasion. Cell Adh. Migr. 4, 348-352 (2010).
32. Michl, P., Knobel, B. & Downward, J. CUTL1 is phosphorylated by protein kinase A, modulating its efects on cell proliferation and motility. J. Biol. Chem. 281, 15138-15144 (2006). (Pubitemid 43855103)
33. Seguin, L. et al. CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP, and MKLP1 in S phase. Mol. Cell Biol. 29, 570-581 (2009).
34. Kedinger, V. et al. p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin. J. Biol. Chem. 284, 27701-27711 (2009).
35. Michl, P. et al. CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7, 521-532 (2005). (Pubitemid 40799246)
36. Aleksic, T. et al. CUTL1 promotes tumor cell migration by decreasing proteasome-mediated Src degradation. Oncogene 26, 5939-5949 (2007).
37. Kunath, T. et al. Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. Nat. Biotechnol. 21, 559-561 (2003). (Pubitemid 36532022)
38. Shouval, D. et al. Tumorigenicity in nude mice of a human hepatoma cell line containing hepatitis B virus DNA. Cancer Res. 41, 1342-1350 (1981). (Pubitemid 11146762)
39. Nomura, F., Ohnishi, K. & Tanabe, Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 64, 1700-1707 (1989). (Pubitemid 19251142)
40. Johnson, P., Melia, W., Palmer, M., Portmann, B. & Williams, R. Relationship between serum alpha-foetoprotein, cirrhosis and survival in hepatocellular carcinoma. Br. J. Cancer 44, 502-505 (1981). (Pubitemid 12231984)
41. Xu, H. et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 52, 1431-1442 (2010).
42. Ledford, A. W. et al. Deregulated expression of the homeobox gene Cux-1 in transgenic mice results in downregulation of p27(kip1) expression during nephrogenesis, glomerular abnormalities, and multiorgan hyperplasia. Dev. Biol. 245, 157-171 (2002). (Pubitemid 34461811)
43. Brantley, J. G., Sharma, M., Alcalay, N. I. & Heuvel, G. B. Cux-1 transgenic mice develop glomerulosclerosis and interstitial fbrosis. Kidney Int. 63, 1240-1248 (2003). (Pubitemid 36349989)
44. Cadieux, C. et al. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cancer Res. 69, 7188-7197 (2009).
45. Cadieux, C. et al. Polycystic kidneys caused by sustained expression of Cux1 isoform p75. J. Biol. Chem. 283, 13817-13824 (2008).
46. Cadieux, C. et al. Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia. Cancer Res. 66, 9492-9501 (2006). (Pubitemid 44623647)
47. Vanden Heuvel, G. B. et al. Hepatomegaly in transgenic mice expressing the homeobox gene Cux-1. Mol. Carcinog. 43, 18-30 (2005). (Pubitemid 40629199)
48. Sansregret, L. et al. Te p110 isoform of the CDP/Cux transcription factor accelerates entry into S phase. Mol. Cell Biol. 26, 2441-2455 (2006). (Pubitemid 43346942)
49. Jopling, C., Yi, M., Lancaster, A., Lemon, S. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specifc MicroRNA. Science 309, 1577-1581 (2005). (Pubitemid 41266486)
50. Taulli, R. et al. Te muscle-specifc microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic diferentiation. J. Clin. Invest. 119, 2366-2378 (2009).
51. Zhou, Y. et al. Chimeric mouse tumor models reveal diferences in pathway activation between ERBB family-and KRAS-dependent lung adenocarcinomas. Nat. Biotechnol. 28, 71-78 (2010).
52. Harada, R. et al. Genome-wide location analysis and expression studies reveal a role for p110 CUX1 in the activation of DNA replication genes. Nucleic Acids Res. 36, 189-202 (2008).
53. Szulc, J., Wiznerowicz, M., Sauvain, M. O., Trono, D. & Aebischer, P. A versatile tool for conditional gene expression and knockdown. Nat. Methods 3, 109-116 (2006). (Pubitemid 43173309)
54. Maeda, S. et al. Ikappa B kinasebeta/nuclear factor-kappaB activation controls the development of liver metastasis by way of interleukin-6 expression. Hepatology 50, 1851-1860 (2009).
55. Elmén, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008). (Pubitemid 351550859)
56. Bai, S. et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 284, 32015-32027 (2009).
57. Yao, X. et al. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin. Cancer Res. 9, 2719-2726 (2003). (Pubitemid 36842118)
58. Kim, M. et al. Generation of orthotopic and heterotopic human pancreatic cancer xenografs in immunodefcient mice. Nat. Protoc. 4, 1670-1680 (2009).